. Author manuscript; available in PMC: 2016 Jan 31.

Published in final edited form as: Cochrane Database Syst Rev. 2015 Jan 31;1:CD006127. doi: 10.1002/14651858.CD006127.pub2

Table 5.

Comparison of ACEi drugs with other classes of anti-hypertensives

Outcome	Trial identifier	Comparator class	RR (95% CI)
Incidence of DR	DEMAND	ACEi + CCB	0.48 (0.13, 1.86)
Progression of DR	UKPDS/HDS	beta-blocker	1.01 (0.75, 1.35)
Combined incidence and progression of DR	ABCD (1)	CCB	1.33 (0.93, 1.92)
	ABCD (2)	CCB	0.93 (0.71, 1.21)
	RASS	ARB	0.89 (0.49, 1.63)
Regression of DR	BENEDICT	non-ACEi	0.44 (0.22, 0.87)
All-cause mortality	UKPDS/HDS	beta-blocker	0.88 (0.64, 1.20)

ACEi: angiotensin-converting enzyme inhibitor

ARB: angiotensin receptor blocker

CCB: calcium channel blocker

DR: diabetic retinopathy

RR: risk ratio

CI: confidence interval